Quest Diagnostics Incorporated (DGX)
NYSE: DGXHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:04 PM ET · Delayed 15 min
After hours: 227.06 +0.04%
DGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $25.06B
- P/E (TTM)
- 24.10
- Forward P/E
- 18.83
- EPS (TTM)
- $9.42
- Dividend yield
- 1.46% ($3.32)
- Ex-dividend date
- Oct 6, 2026
- 52-week range
- 171.18 – 248.84
- Day range
- 226.81 – 229.80
- Volume / Avg
- 927.41K / 1.04M
- Beta
- —
- Shares outstanding
- 110.37M
- Next earnings
- Oct 22, 2026
52-week range
DGX stock today
Quest Diagnostics (DGX) closed at $227.06 on Oct 7, down 0.58% (-$1.33), versus the S&P 500's 0.22% decline. Shares are 8.8% below their 52-week high of $248.84, set on Sep 21, 2026 and 32.6% above the 52-week low of $171.18, in the middle of the past year's range. DGX is up 31.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 25.3%.
At 24.1x trailing earnings, Quest Diagnostics trades in line with the peer-group median of 25.5x. Its forward P/E of 18.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 22 before the market opens; analysts expect EPS of $2.85. Quest Diagnostics pays an annual dividend of $3.32 per share, a 1.46% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Quest Diagnostics
Company profileQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. James E. Davis
- Headquarters
- Secaucus, NJ
- Employees
- 46,000
- Website
- questdiagnostics.com
Financial highlights
Full financialsIn fiscal 2025, Quest Diagnostics generated $11.04 billion in revenue, up 11.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $992.0 million (+13.9% year over year), for a net margin of 9.0% versus a median of 9.6% in the prior 5 years. Gross margin was 33.2% (up from 32.9%) and operating margin 14.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Growth | +11.78% | +6.70% | -6.38% | -8.39% | +14.32% |
| Net income | $992.00M | $871.00M | $854.00M | $946.00M | $2.00B |
| EPS (diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Analyst forecast
ForecastConsensus (17 analysts)
buy
Avg. price target
$248.07+9.25%
- Strong buy 2
- Buy 7
- Hold 7
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 22, 2026
- EPS estimate
- $2.85
- Last reported (Q2 2026)
- Jul 23, 2026
- EPS actual vs est.
- $2.84 vs —
Dividends
Dividend history- Annual dividend
- $3.32
- Dividend yield
- 1.46%
- Last payment
- $0.86
- Ex-dividend date
- Oct 6, 2026
DGX news
All DGX newsQuest Diagnostics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LHLabcorp Holdings Inc. | 311.97 | +0.08% | $25.30B | vs DGX |
| GHGuardant Health Inc. | 168.33 | -1.38% | $22.59B | vs DGX |
| CNCCentene Corporation | 64.99 | +0.59% | $32.10B | vs DGX |
| MOHMolina Healthcare Inc | 194.82 | -0.18% | $10.17B | vs DGX |
| OSCROscar Health Inc. Class A | 32.91 | +1.76% | $10.16B | vs DGX |
| ILMNIllumina Inc. | 267.76 | -2.11% | $40.43B | vs DGX |
| HSICHenry Schein Inc. | 83.66 | -1.39% | $9.32B | vs DGX |
| CAICaris Life Sciences Inc. | 27.10 | -1.29% | $7.66B | vs DGX |
Indexes, lists and sector
Index membership
Appears in lists
Quest Diagnostics stock FAQ
What is Quest Diagnostics's stock price today?
DGX last traded at $227.06 as of Oct 7, 4:04 PM EDT, down 0.58% on the day. Prices are delayed at least 15 minutes.
Does Quest Diagnostics pay a dividend?
Yes. Quest Diagnostics pays $3.32 per share annually, a 1.46% yield. The most recent dividend of $0.86 had an ex-dividend date of Oct 6, 2026.
When is Quest Diagnostics's next earnings date?
Quest Diagnostics is expected to report earnings on Thursday, October 22, 2026. Analysts expect EPS of $2.85.
What is DGX's P/E ratio?
DGX trades at a trailing P/E ratio of 24.10 and a forward P/E of 18.83, compared with a median of 25.5 for its closest peers.
Is Quest Diagnostics in the S&P 500?
Yes. Quest Diagnostics (DGX) is a constituent of the S&P 500 index.
Who is Quest Diagnostics's CEO?
Mr. James E. Davis is the chief executive officer of Quest Diagnostics Incorporated, which has about 46,000 employees.
Has DGX ever split its stock?
Yes. The most recent DGX stock split was a 2-for-1 split on Jun 21, 2005, one of 2 splits on record.